ClinicalTrials.gg
CompletedNCT04662190Updated Jun 1, 2026

Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.

An interventional study of 3D printing model/guide. and Standard surgery in Thyroid Associated Ophthalmopathy and Surgical Procedure, Unspecified, sponsored by Althaia Xarxa Assistencial Universitària de Manresa. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Althaia Xarxa Assistencial Universitària de Manresa · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicentric, randomized, single-blinded clinical trial to evaluate the efficacy and safety of 3D printing for the planification and simulation of orbital decompression surgery for thyroid-associated orbitopathy.

02

Conditions studied

  • Thyroid Associated Ophthalmopathy
  • Surgical Procedure, Unspecified

Browse trials for

03

In context

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

This study's enrollment of 12 is below the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.

Browse Graves Ophthalmopathy studies →

Lead sponsor

Althaia Xarxa Assistencial Universitària de Manresa is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of inactive thyroid-associated orbitopathy requiring bilateral orbital decompression (moderate-severe in EUGOGO classification).
  • Volunteers older than 18 years old.
  • Ability to read.
  • Acceptation to participate and signature of .

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old.
  • Previous orbital surgery.
  • Any coexisting disease preventing follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Control grup

    Conventional surgery.

    Procedure: Standard surgery

  • Experimental
    Intervention group

    Surgery planned, simulated and guided by 3D printing.

    Device: 3D printing model/guide.

Interventions

  • Device3D printing model/guide.

    Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.

  • ProcedureStandard surgery

    Orbital decompression surgery will be previously planned and simulated using the actual standard methods.

06

What researchers measure

Primary outcomes

  1. Intraoperative complications

    Intraoperative complications

    Time frame: 6 months

  2. Postoperative complications

    Postoperative complications

    Time frame: 6 months

  3. Exophthalmos

    Exophthalmos measured in millimeters

    Time frame: 6 months

  4. Diplopia

    Diplopia correction

    Time frame: 6 months

07

Study locations

1 site
  • Eduard Pedemonte Sarrias
    Manresa, Barcelona 08243, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Mar 2026, 56 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2020
First posted
Dec 10, 2020
StartActual
Jul 5, 2021
Primary completionActual
Mar 30, 2026
CompletionActual
Mar 30, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04662190
Lead sponsor
Althaia Xarxa Assistencial Universitària de Manresa
Collaborators
Societat Catalana d'Oftalmologia
Responsible party
Eduard Pedemonte-Sarrias (Ophthalmologist, MD, PhD, Althaia Xarxa Assistencial Universitària de Manresa) — Principal investigator
First posted
Dec 10, 2020
Start date
Jul 5, 2021
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
Jun 1, 2026

Study contacts

Eduard Pedemonte-Sarrias, Md, PhD
principal investigator · Althaia Xarxa Assistencial Universitària de Manresa

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion